Discovery of 177Lu-PSMA-MN4 as an improved PSMA-targeted radioligand with enhanced antitumor efficacy. (PubMed, Eur J Med Chem) - Sep 30, 2026 - "Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lu-PSMA-617 improves outcomes in metastatic castration-resistant prostate cancer (mCRPC), yet a substantial subset of patients experiences disease progression, underscoring the need for next-generation agents with improved pharmacological profiles...These findings position 177Lu-PSMA-MN4 as a promising candidate for next-generation PSMA-targeted radioligand therapy. Collectively, this work establishes a structure-guided linker-optimization paradigm for PSMA radioligands and identifies 177Lu-PSMA-MN4 as a promising preclinical candidate that warrants further translational evaluation."
Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Disorders • Oncology • Prostate Cancer • Solid Tumor
|
|
Chenchen Cai; Chunmiao Qu; Kai Lv; Manchao Song; Mingjie Zhang; Peishang Li; Sheng Zhou; Xiangsheng Kong; Xue Wang; Yuechen Li; Zhiqian Wang
|